An interface is a standing dependency on software you do not control. APIs get deprecated, data models change, authentication methods move, a field is renamed, a vendor is acquired and its roadmap changes. None of that is unreasonable and all of it lands on you. Which means an integration is not a project that finishes. It is a liability with a maintenance cost, a release calendar to watch and an owner who has to exist.
We build and operate clinical system integrations across CTMS, EDC, eTMF and eISF, IRT, eCOA and ePRO, laboratory systems, safety databases and EHR where permitted: API development where interfaces exist, event-driven synchronisation, secure file exchange where that is what the vendor offers, reconciliation built into the interface rather than bolted on afterwards, and monitoring that detects a vendor change before a study does. Your quality and regulatory functions set the validation requirements. We build to satisfy them and to keep satisfying them after the vendor ships.
Clinical integration estates degrade in a specific and predictable way. An interface is built for a study, works, and the project closes. The vendor releases an update eight months later and the interface starts failing, or worse, keeps succeeding against a field that now means something slightly different. Nobody was watching the vendor’s release notes because nobody was assigned to. The failure surfaces as a data problem in a study, is diagnosed as a data problem, and gets fixed by whoever is available. Multiply that by thirty interfaces and five vendors and the estate becomes something the organization is afraid to touch.
The second structural problem is that each interface looks cheap in isolation. Connecting two systems is a well-understood piece of engineering, and the first few are genuinely straightforward. The cost that surprises people is not the build, it is that the number of connections grows faster than the number of systems, that every one of them is a validation artefact in a regulated estate, and that each carries a permanent share of somebody’s attention. Organizations rarely decide to accumulate an unmaintainable integration estate. They decide to build one more point-to-point interface, about forty times.
No interface has a named owner
So nobody watches the vendor release notes that will break it.
Point-to-point is cheap each time
And the total grows faster than the number of systems does.
The interface succeeds and the data is wrong
A renamed or repurposed field parses cleanly and means something else.
Reconciliation was left downstream
So the interface cannot prove it delivered what the source actually held.
The contract did not permit the integration
Discovered after the architecture, which is the expensive order.
Each study rebuilds the same vendor connection
Because nothing was built to be reused across studies.
Delivery was confirmed and records were rejected
The sender got a success response and the receiver dropped half the file.
Three parties, no single owner
Sponsor, CRO and site, and the site is running eleven other studies.
Inventory your interfaces and write a name next to each one. List every integration in the estate and record, for each: what it connects, who built it, who owns it now by name, when it was last changed, whether anybody monitors the vendor release calendar for either end, and what happens if it fails on a Friday. The uncomfortable finding is consistent across organizations: a handful are well owned, a long tail has no owner at all, and several of the unowned ones are load-bearing for an active study. That inventory takes a week, needs nothing but conversations, and is the single highest-value piece of work available to a clinical systems function that has never done it.
Two things sit earlier here than in most integration methods. The commercial and licensing position is established during assess, because it constrains the architecture. And the monitoring design happens alongside the build rather than after go-live, because an interface without detection is an interface whose failures are discovered by a study team.
Step 1
Assess the systems, the interfaces and the contracts
Step 2
Map the flows, name the owners and fix the system of record
Step 3
Architect for reuse rather than per study
Step 4
Standardize the canonical form in the middle
Step 5
Integrate through the most durable mechanism available
Step 6
Validate the interface to its intended use
Step 7
Secure in transit and at rest, with least privilege
Step 8
Monitor delivery, latency, reconciliation and vendor releases
Step 9
Optimize, consolidate and retire
Count how many times you have integrated the same vendor. Pick the central laboratory, imaging provider or eCOA vendor you use most often and count how many separate integrations to it exist across your active and recent studies, how many transfer specifications, and how many validation packages. The number is usually close to the number of studies. Then ask what it would have cost to build one and configure it ten times. That comparison is the business case for treating integration as infrastructure, and it is a calculation the organization can do from records it already has.
Most engagements start with one problematic interface or one vendor integrated too many times. That produces the inventory and the reuse argument, which is what makes the rest fundable.
System connections
CTMS integration for study, site, milestone and operational data in both directions
EDC integration including incremental extraction and resilience to mid-study build changes
eTMF and eISF connectivity for document flow, metadata and status synchronisation
IRT integration for randomisation and supply, with blinding-aware handling by design
eCOA and ePRO integration including device and timing metadata, not only responses
Central laboratory, imaging and specialty vendor onboarding as reusable connections
Safety system connectivity for case-relevant data flow under your pharmacovigilance procedures
EHR to EDC integration where consent, permitted use and source data positions allow it
How the connection is made
API development and consumption, including the API you expose to partners and sites
Event-driven integration where systems emit events, so downstream work starts on the event
Secure file exchange engineered properly where that is what the vendor offers
Middleware and integration engine implementation as the single place flows are defined
Canonical entity models for study, site, subject, visit and specimen
Identifier mapping maintained as a governed artefact, because an unmanaged mapping misassociates records rather than merely failing to match them
Clinical data synchronisation with conflict rules decided rather than discovered
Keeping it alive
Reconciliation built into the interface, proving delivery against what the source held
Interface monitoring covering availability, latency, volume and content anomalies
Vendor release tracking, with regression testing before an update reaches production
Named ownership, runbooks and an escalation path for every interface we build
Validation evidence produced as a build deliverable, scoped to intended use
Dealing with what exists
Interface inventory and ownership assessment across the current estate
Legacy system modernisation, including replacing fragile interface automation with APIs
Consolidation of duplicated per-study integrations into reusable vendor connections
Decommissioning of interfaces nothing depends on, under change control
A connection inside your own estate is an engineering problem. A connection between a sponsor, a CRO, a vendor and a site is an engineering problem wrapped in a commercial one, with no single party able to decide, and that is most of this list.
| Integration | What it carries | The thing that makes it hard |
|---|---|---|
| Sponsor to CRO data exchange | Operational, clinical and financial study data | Contractual scope, separation, and two sets of conventions |
| Site to sponsor connectivity | Documents, status, queries, essential records | The site chose none of your systems and runs eleven other studies |
| EDC to safety database | Event and case-relevant data | A standing reconciliation obligation, not a one-time transfer |
| Central laboratory to EDC and warehouse | Results, units, methods, ranges, specimen identity | Identity by sample, and method changes mid-study |
| EHR to EDC | Routine care data as source where permitted | Consent scope and source data verification position govern everything |
| IRT to CTMS and supply | Randomisation, kit assignment, resupply | Treatment-revealing, so access design precedes integration design |
| eCOA and ePRO to EDC | Patient-reported data, compliance, device metadata | Timing metadata matters as much as the response value |
| Study startup systems | Documents, approvals, activation status | Many parties, sequential habits, and no shared system |
| Patient enrolment synchronisation | Screening, consent, randomisation status | Several systems claim to hold subject status and they disagree |
| Protocol amendment propagation | Changed structures, documents, training records | Episodic and content-specific, so automate propagation not interpretation |
| Vendor onboarding | A new provider for an existing study | Speed, because the study is already enrolling |
| Study closeout and archive | Final datasets, documents, reconciliation evidence | Proving completeness, which needs the expected set derived from the protocol |
Standards in this estate solve different problems and are not interchangeable. The common error is selecting one as a strategy and then forcing systems that do not speak it to pretend. The workable position is to use each where it fits and to translate at the boundary, with the canonical form in the middle.
| Mechanism | What it is for | Where it does not fit |
|---|---|---|
| REST APIs | Current system-to-system exchange where the vendor exposes one | Bulk historical loads, and systems that offer no interface |
| HL7 FHIR | Exchanging health information with clinical care systems | Trial data structures, which it was not designed to model |
| HL7 v2 | Established messaging with healthcare and laboratory systems | Storage or analysis, and anything needing rich structure |
| CDISC ODM | Exchanging study metadata and clinical data between study systems | An analysis or warehouse model |
| CDISC submission structures | Presenting study data for regulatory review | A working model for integration or cross-study analysis |
| IHE profiles | Constraining how standards are used so two implementations interoperate | Replacing the underlying standards or the mapping work |
| Event-driven messaging | Starting downstream work the moment something happens | Guaranteed ordering and bulk reconciliation without extra design |
| Secure file exchange | Vendors whose offer is a scheduled file, which is many of them | Low latency, and anything needing a response |
Test against the vendor instance, not the documentation. API documentation describes what was intended. The instance tells you what exists: which endpoints are actually available on your licence tier, what the real rate limits are, which fields are populated in practice rather than in the schema, how errors are returned, whether pagination behaves as described, and what happens under the volume you will actually send. Getting a sandbox credential and spending two days probing it before the design is finalised prevents the category of problem that otherwise appears during integration testing, when the architecture is already committed and the study has a date.
An interface in a regulated estate is a computerized system component with a lifecycle. The part organizations underestimate is that the lifecycle includes changes they did not initiate, because a vendor update to a system at either end can invalidate the evidence that the interface performs as intended. Which frameworks apply, how an interface is classified and what validation it requires are determined by your quality and regulatory functions.
Frameworks where they apply
- ICH E6 Good Clinical Practice principles for the conduct of clinical research
- GxP and GAMP 5 risk-based lifecycle approaches where your quality function has adopted them
- FDA 21 CFR Part 11 and EU Annex 11 for electronic records and signatures where applicable
- Computerized system validation scoped to the intended use your quality function assigns
Security
- Encryption in transit and at rest, with key management owned rather than assumed
- Least privilege for every integration identity, reviewed when scope changes
- Credential and secret management with rotation, and no credentials in configuration files
- Role-based access on both ends, with sponsor and study separation where required
Privacy
- HIPAA where protected health information crosses an interface
- GDPR and equivalent regimes, including lawful basis for each transfer
- Cross-border transfer and residency requirements per jurisdiction
- Minimisation, so an interface carries what the purpose needs and not the whole record
Integrity and change
- Audit trail of transfers, transformations, failures and corrections, attributable to the interface itself rather than appearing as actions taken by a person
- Source to target traceability, so a value can be followed back through the transformation
- Change control covering interface logic, mappings, canonical models and configuration
- Re-validation triggered by vendor release, standard revision or specification change
Integration monitoring usually watches whether jobs ran. The failures that matter in clinical work are the ones where the job ran, reported success, and delivered fewer records than the source held or the right number of records with the wrong content.
| Failure | How it presents |
|---|---|
| A transfer succeeds short | Job green, fewer records than the source held, nobody counted |
| A field is renamed or repurposed | Parsing succeeds against the wrong thing and the values look plausible |
| A vendor resends or corrects a file | Records duplicate or change, and the earlier reconciliation is now wrong |
| A retry re-performs a completed transfer | Duplicates in a regulated record that somebody has to unpick and explain |
| Latency grows without failing | Data is arriving, later each week, and a study team is making decisions on stale information |
| A credential expires | The interface stops cleanly and the alert goes to a mailbox nobody reads |
| Records arrive out of sequence | A later update lands before the earlier event and the destination holds the wrong state |
| An identifier scheme drifts | Match rates fall, unmatched records accumulate, and coverage quietly narrows |
| A rate limit is reached | Partial delivery that looks like a partial day rather than an error |
Integration programmes report interfaces delivered. The outcomes that matter are whether manual transfers stopped, whether data arrives when expected, and whether vendor releases became planned work instead of incidents.
| Outcome | How to tell |
|---|---|
| Manual transfers reduced | The spreadsheet and the scheduled email are gone, not running in parallel |
| Data consistency improved | Systems agree, and where they differ the authoritative source is defined |
| Exchange accelerated | Latency from source event to availability is measured and falling |
| Interoperability strengthened | A new vendor is a configuration exercise, not an integration project |
| Integration errors minimized | Reconciliation runs inside each interface and the exception backlog is owned |
| Visibility improved | Anybody can see what arrived, when, and whether it reconciled |
| Execution more reliable | Vendor releases are assessed and tested in advance rather than discovered |
We work with sponsors, CROs and sites on clinical systems integration: contracts and licensing established before the architecture, vendor connections built once and configured per study, reconciliation inside the interface, monitoring that catches degradation rather than only failure, and vendor release management so an update is planned work. Your legal, privacy, clinical and quality functions set the permissions, the meaning and the validation requirements.
CaliberFocus builds and operates clinical system integrations for sponsors, CROs and sites across CTMS, EDC, eTMF, IRT, eCOA, laboratory and safety systems. We establish contracts and licensing before the architecture, build vendor connections once and configure them per study, reconcile inside the interface, and manage vendor releases so an update is planned work rather than an incident.
- Every interface inventoried with a named owner
- Reusable vendor connections configured per study
- Reconciliation and monitoring built into each interface
- Vendor releases assessed and regression-tested in advance
Security & Compliance
